<DOC>
	<DOCNO>NCT01093586</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor umbilical cord blood transplant ( UCBT ) help stop growth cancer abnormal cell help stop patient 's immune system reject donor 's stem cell . When stem cell unrelated donor , exactly match patient 's blood , infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving antithymocyte globulin transplant cyclosporine mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well donor umbilical cord blood stem cell transplant work treat patient hematologic malignancy .</brief_summary>
	<brief_title>Donor Umbilical Cord Blood Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : 1 . To establish day +180 overall survival myeloablative unrelated double unit UCBT single institution set . SECONDARY OBJECTIVES : 1 . To determine rate hematologic immune reconstitution patient high risk hematologic malignancy , undergo myeloablative chemotherapy follow infusion double unit UCBT . 2 . To determine contribution umbilical cord unit immune reconstitution focus initial ( day +21 BM , +28 PB ) sustain engraftment ( day +100 BM ; PB +14 , +21 , +28 , +35 , +42 , +60 , +100 , +180 , +1 2 year ) . 3 . To determine probability overall survival disease free survival one two year . 4 . To describe incidence disease recurrence one two year patient post UCBT . 5 . To describe incidence acute GVHD chronic GVHD 100 day one year , respectively . 6 . To determine incidence day 100 180 treatment related mortality . 7 . To determine incidence serious infectious complication first year transplant . 8 . To determine incidence donor-derived neutrophil platelet recovery . 9 . To determine incidence secondary lymphoproliferative disease follow transplantation umbilical cord blood . OUTLINE : PREPARATIVE REGIMEN : Patients receive oral busulfan every 6 hour day -8 -5 , cyclophosphamide IV day -4 -3 , anti-thymocyte globulin methylprednisolone IV day -3 -1 . TRANSPLANTATION : Patients undergo double-unit umbilical cord blood allogeneic stem cell transplantation day 0 . GRAFT-VS-HOST DISEASE PROPHYLAXIS : Beginning day -2 , patient receive cyclosporine IV taper begin day 100 . Patients also receive mycophenolate mofetil IV orally every 8 hour day -3 45 . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Prolymphocytic</mesh_term>
	<mesh_term>Leukemia , Monocytic , Acute</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Leukemia , Erythroblastic , Acute</mesh_term>
	<mesh_term>Leukemia , Megakaryoblastic , Acute</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<criteria>Patients diagnose one follow hematological malignancy : acute myelogenous leukemia ( AML ) , acute lymphoblastic leukemia , nonHodgkin 's lymphoma , myelodysplastic syndrome ( MDS ) , chronic myelogenous leukemia ( CML ) , myeloproliferative lymphoproliferative disorder AMLFirst remission ( CR1 ) high risk feature include know prior diagnosis myelodysplasia ( MDS ) ; therapy related AML ; white cell count presentation &gt; 100,000 ; presence extramedullary leukemia diagnosis ; unfavorable AML subtype ( M0 , M5M7 ) ; poor cytogenetic marker ( abnormality chromosome 5 , 7 8 , 11q23 , Philadelphia chromosome , complex karyotype ) AMLSecond remission ( CR2 ) subsequent remission AMLRelapse/Persistent Disease &lt; 20 % bone marrow blast ALLFirst remission ( CR1 ) high risk relapse define : B cell ALL white blood cell count ( WBC ) presentation &gt; 30,000 ( T cell ALL WBC &gt; 100,000 ) ; presence highrisk cytogenetic abnormality ( 9 ; 22 ) , ( 1 ; 19 ) , ( 4 ; 11 ) MLL rearrangement ( 11q23 ) , ( 8 ; 14 ) ALLSecond remission ( CR2 ) subsequent remission ALLRelapse/Persistent Disease &lt; 20 % bone marrow blast NonHodgkin LymphomaInduction failure relapse sensitive recent chemotherapy MDSLow Intermediate1 International Prognostic Scoring System ( IPSS ) score : lifethreatening cytopenia ( ) ; and/or red cell platelet transfusion dependence MDSANC &lt; 500 , recurrent infection , PRBC transfusion &gt; 2 units/month , poor risk cytogenetics , platelet transfusion dependence MDSIntermediate2 High IPSS score CMLChronic phase I ( CP1 ) resistant intolerant tyrosine kinase inhibitor ( i.e . imatinib , dasatinib , etc . ) CMLCP2 subsequent chronic phase , include chronic phase achieve induction therapy blast crisis Myeloproliferative lymphoproliferative disorderseligibility determine consensus physician Case Comprehensive Cancer Center Leukemia/Lymphoma Multidisciplinary Committee Myeloproliferative lymphoproliferative disordersmust evidence disease acceleration candidate umbilical cord blood transplant ; myeloproliferative disorder eligible transplant include chronic myelomonocytic leukemia ( CMML ) high IPSS score myelofibrosis Myeloproliferative lymphoproliferative disorderspotential lymphoproliferative disorder eligible transplant include chronic lymphocytic leukemia , prolymphocytic leukemia , large granular lymphocytic leukemia Good performance status : Karnofsky &gt; = 70 % ECOG 01 Calculated creatinine clearance &gt; = 60 mL/min , measure creatinine clearance &gt; = 60 mL/min ( 24hour urine collection ) creatinine &gt; = 1.5 history renal dysfunction Hepatic Transaminases &lt; 4 x upper limit normal ( ULN ) ; total bilirubin &lt; 2.5 mg/dL , unless patient history benign congenital hyperbilirubinemia ( Gilbert 's syndrome ) Normal cardiac function echocardiogram radionuclide scan , ( leave ventricular ejection fraction &gt; 45 % ) ; leave ventricular ejection fraction 4050 % , clearance adult cardiologist require Pulmonary function test demonstrate FEV1 &gt; 60 % predict age Adults must DLCOva &gt; 60 % normal For patient unable complete pulmonary function test clearance adult pulmonologist require Patients eligible clinical trial follow condition : NOT HLAA/B/DR B1 identical RELATED bone marrow donor ; NOT 6/6 HLAidentical match unrelated adult donor ; OR match related donor transplant best interest patient ( i.e. , patient 's condition precludes wait donor , much time prepare donor , donor ineligible due medical reason , case high risk disease relate donor appropriate ( syngeneic transplant ) ; decision must agree upon consensus physician Case Comprehensive Cancer Center Leukemia/Lymphoma Multidisciplinary Committee ; OR condition precludes wait search find donor National Marrow Donor Registry Female patient pregnant breastfeed HIV HTLV1 positivity Any leukemia morphologic relapse persistent disease BM &gt; = 20 % blast ( cytogenetic relapse without morphologic evidence relapse , cytogenetic persistent disease acceptable ) Active extramedullary leukemia , include CNS disease Prior hematopoietic stem cell transplant ( autologous allogeneic ) Uncontrolled infection Patient identical relate bone marrow donor 6/6 HLAidentical match unrelated donor Any patient unable provide inform consent comply requirement protocol</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>